针对瘤细胞内在的ITGB2轴,可以抑制黑色素瘤的进展
Erik Rasbach1,2,3, Laure Migayron1,2, Anne Brandenburg1,4
1Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Molecular cancer
|December 18, 2025
概括
这项研究揭示了整合素α-M (ITGB2) 在黑色素瘤细胞中表达,通过ITGB2:ICAM-1:Wnt信号轴促进瘤生长和转移. 针对这一轴为黑色素瘤提供了一个新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 集成蛋白β-2 (ITGB2) 是免疫细胞功能的关键调解剂,传统上被认为是血液细胞独有的.
- 在癌细胞本身,特别是黑色素瘤等固体瘤中,ITGB2的作用基本上尚未被探索.
- 了解非造血性ITGB2功能对于确定新的癌症治疗点至关重要.
研究的目的:
- 研究瘤细胞内在的ITGB2的功能表达和原始原始作用.
- 阐明由癌细胞内在的ITGB2驱动的分子机制和信号通路.
- 评估ITGB2作为潜在的治疗点在黑色素瘤进展和转移.
主要方法:
- 使用多组学 (单细胞和散装RNA测序) 和分子生物学技术 (qPCR,免疫光,流细胞计,免疫阻塞).
- 在黑色素瘤细胞系和患者样本中评估ITGB2介导的粘附和扩散.
- 在体内使用的黑色素瘤模型 (NSG,野生型,Icam1 KO小鼠) 和ITGB2轴的遗传/药理向 (CRISPR/Cas9,抗体,Wnt抑制剂).
主要成果:
- 在黑色素瘤细胞中证明ITGB2的非血液构造表达,与瘤进展和转移相关.
- 在临床前模型中展示了ITGB2-ICAM-1相互作用,促进黑色素瘤细胞粘附,瘤生长和转移性传播.
- 通过ITGB2:ICAM-1轴确定了下游Wnt信号的激活,其抑制抑制了瘤生长.
结论:
- 推翻了关于ITGB2仅限于免疫细胞的既定观点,揭示了它在黑色素瘤中的重要作用.
- 建立了一个新的原始起源轴:瘤细胞内在的ITGB2:ICAM-1:Wnt信号传递.
- 验证了这一轴作为黑色素瘤治疗的有希望和可行的治疗目标.
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
01:31The Intrinsic Apoptotic Pathway
8.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.2K
02:38Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
02:07Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K